BioPharma
This proprietary homogeneous nanosuspension has a solution-like appearance which offers great comfort to the eyes and enhanced drug penetration into ocular...
May 05, 2023 | News
-Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances A...
May 01, 2023 | News
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 ...
April 28, 2023 | News
The newly created business leverages the acclaimed team and production facility recently acquired by Bridgewest Group from Pfizer (Perth) Pty Ltd, a subsid...
April 26, 2023 | News
The Phase 3 trial is a randomized, controlled, open-label, multi-center study to evaluate the efficacy and safety of lemzoparlimab in combination with AZA ...
April 25, 2023 | News
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-...
April 25, 2023 | News
The launch of this early-access program in Hainan marks the beginning of a new treatment era for IgA nephropathy in China, where Everest can...
April 24, 2023 | News
The company has been notified by the FDA that the Phase 1/2 clinical trial may proceed The latest preclinical data explored the antitumor effica...
April 24, 2023 | News
The FDA has extended the Prescription Drug User Fee Act (PDUFA) action date by three months to July 24, 2023 to allow additional time to review requested u...
April 21, 2023 | News
Veeva Systems (NYSE: VEEV) today released the latest Veeva Pulse Field Trends Report, the largest analysis of global healthcare professiona...
April 20, 2023 | News
CBC Group ("CBC"), Asia's largest healthcare-dedicated investment firm headquartered in Singapore, and Hasten Biopharmaceutic Company Limite...
April 20, 2023 | News
Staffed with a team of highly skilled research, application and formulation experts, the new $25 million center will be an advanced training and coll...
April 20, 2023 | News
"Receiving FDA approval on our HPAPI fill line is an exciting milestone for our company, and couldn't have happened without the hard work, hours of prepara...
April 20, 2023 | News
Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towa...
April 18, 2023 | News
Most Read
Bio Jobs
News